InspireMD (NSPR) 10-K 8 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 08, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	InspireMD, Inc.
Entity Central Index Key	0001433607
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 15,616,214
Entity Common Stock, Shares Outstanding		117,832,226
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 12,645	$ 5,514
Accounts receivable:
Trade, net	476	823
Other	146	150
Prepaid expenses	334	87
Inventory	1,415	1,236
Receivable for sale of Shares	323
TOTAL CURRENT ASSETS	15,339	7,810
NON-CURRENT ASSETS:
Property, plant and equipment, net	448	547
Operating lease right of use assets	1,265	937
Fund in respect of employee rights upon retirement	725	586
TOTAL NON-CURRENT ASSETS	2,438	2,070
TOTAL ASSETS	17,777	9,880
Accounts payable and accruals:
Trade	236	646
Other	3,469	2,469
TOTAL CURRENT LIABILITIES	3,705	3,115
LONG-TERM LIABILITIES:
Operating lease liabilities	999	653
Liability for employee rights upon retirement	910	729
TOTAL LONG-TERM LIABILITIES	1,909	1,382
COMMITMENTS AND CONTINGENT LIABILITIES (Note 6)
TOTAL LIABILITIES	5,614	4,497
EQUITY:
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2020 and 2019; 49,264,830 and 3,916,134 shares issued and outstanding at December 31, 2020 and 2019, respectively	5
Additional paid-in capital	180,334	163,015
Accumulated deficit	(168,176)	(157,632)
Total equity	12,163	5,383
Total liabilities and equity	17,777	9,880
Preferred B Shares [Member]
EQUITY:
Preferred stock, value
Preferred C Shares [Member]
EQUITY:
Preferred stock, value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	49,264,830	3,916,134
Common stock, shares outstanding	49,264,830	3,916,134
Preferred B Shares [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	500,000	500,000
Preferred stock, shares issued	17,303	17,303
Preferred stock, shares outstanding	17,303	17,303
Preferred C Shares [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,172,000	1,172,000
Preferred stock, shares issued	2,343	34,370
Preferred stock, shares outstanding	2,343	34,370

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
REVENUES (2020 - net of settlement payment of $580, see note 6)	$ 2,485	$ 3,721
COST OF REVENUES	2,402	2,965
GROSS PROFIT	83	756
OPERATING EXPENSES:
Research and development	2,233	2,954
Selling and marketing	2,103	2,396
General and administrative	6,127	5,222
Total operating expenses	10,463	10,572
LOSS FROM OPERATIONS	(10,380)	(9,816)
FINANCIAL EXPENSES	(160)	(200)
LOSS BEFORE TAX EXPENSES	(10,540)	(10,016)
TAX EXPENSES	4	24
NET LOSS	$ (10,544)	$ (10,040)
NET LOSS PER SHARE - basic and diluted	$ (0.46)	$ (4.80)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic and diluted	22,686,590	2,089,964

Consolidated Statements of Op_2

Consolidated Statements of Operations (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Income Statement [Abstract]
Payment for complaint	$ 580

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Common Stock [Member]		Series B Convertible Preferred Stock [Member]		Series C Convertible Preferred Stock [Member]		Additional Paid-in Capital [Member]	Accumulated Deficit [Member]		Total
Balance at Dec. 31, 2018		[1]		[1]		[1]	$ 156,355	$ (147,592)		$ 8,763
Balance, shares at Dec. 31, 2018	768,615		17,303		61,423
Net loss								(10,040)		(10,040)
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of issuance costs		[1]					6,335			6,335
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of issuance costs, shares	3,039,161
Conversion of Series C Convertible Preferred Stock to common shares		[1]		[1]		[1]			[1]		[2]
Conversion of Series C Convertible Preferred Stock to common shares, shares	38,614				(27,053)
Share-based compensation related to restricted stock , restricted stock units and stock options award, net of forfeitures of shares		[1]		[1]		[1]	325			325
Share-based compensation related to restricted stock , restricted stock units and stock options award, net of forfeitures of shares, shares	69,744
Balance at Dec. 31, 2019		[1]		[1]		[1]	163,015	(157,632)		5,383
Balance, shares at Dec. 31, 2019	3,916,134		17,303		34,370
Net loss								(10,544)		(10,544)
Conversion of Series C Convertible Preferred Stock to common shares		[1]				[1]					[1]
Conversion of Series C Convertible Preferred Stock to common shares, shares	372,173				(32,027)
Share-based compensation related to restricted stock , restricted stock units and stock options award, net of forfeitures of shares		[1]					606			606
Share-based compensation related to restricted stock , restricted stock units and stock options award, net of forfeitures of shares, shares	2,726,165
Exercise of pre-funded warrants	$ 2						16			18
Exercise of pre-funded warrants, shares	14,856,400
Settlement of restricted stock units in shares of common stock		[1]									[1]
Settlement of restricted stock units in shares of common stock, shares	165,000
Issuance of common shares, including at the market offering net of issuance costs	$ 3						15,197			15,200
Issuance of common shares, including at the market offering net of issuance costs, shares	24,108,771
Exercise of Warrants F		[1]					1,418			1,418
Exercise of Warrants F, shares	2,866,600
Exercise of Unit Purchase Option		[1]					82			82
Exercise of Unit Purchase Option, shares	253,587
Balance at Dec. 31, 2020	$ 5	[1]		[1]		[1]	$ 180,334	$ (168,176)		$ 12,163
Balance, shares at Dec. 31, 2020	49,264,830		17,303		2,343
[1]	Represents an amount less than $1
[2]	Represents an amount less than $1 thousand

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 1,110	$ 1,177
Restricted stock award, shares	55,755	838

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,544)	$ (10,040)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	151	158
Loss from sale of property, plant and equipment	14
Change in liability for employees rights upon retirement	181	124
Non cash financial expense (income)	(4)	8
Net change in operating lease assets and liabilities	56	78
Share-based compensation expenses	606	325
Gains on amounts funded in respect of employee rights upon retirement, net	(18)	(35)
Changes in operating asset and liability items:
Increase in prepaid expenses	(247)	(6)
Decrease (Increase) in trade receivables	347	(107)
Decrease (increase) in other receivables	4	(46)
Increase in inventory	(179)	(102)
Decrease in trade payables	(410)	(283)
Increase in other payables	962	116
Net cash used in operating activities	(9,081)	(9,810)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment	(88)	(284)
Proceeds from sale of property, plant and equipment	22
Amounts withdrawn in respect of employee rights upon retirement, net	(121)	(103)
Net cash used in investing activities	(187)	(387)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares and warrants and exercise of Pre-Funded Warrants and unit purchase option, net of $1,110 and $1,177 issuance costs, respectively	16,395	6,335
Net cash provided by financing activities	16,395	6,335
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	4	(8)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	7,131	(3,870)
BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	5,514	9,384
BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR	12,645	5,514
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Acquisition of right-of-use assets by means of lease liabilities	619	67
Receivable for Shares	$ 323

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Issuance costs	$ 1,110	$ 1,177
Pre-Funded Warrants and Unit Purchase Option [Member]
Issuance costs	$ 1,110	$ 1,777

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	NOTE 1 - DESCRIPTION OF BUSINESS a. General InspireMD, Inc., a Delaware corporation (the “Company”), together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary MicroNet™ stent platform technology for the treatment of complex vascular and coronary disease. MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Company’s carotid product (CGuard™ EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company’s coronary product combining MicroNet and a bare-metal stent (MGuard Prime™ EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Company markets its products through distributors in international markets, mainly in Europe. As of the date of issuance of the consolidated financial statements, the Company has the ability to fund its planned operations for at least the next 12 months. However, the Company expects to continue incurring losses and negative cash flows from operations until its products (primarily CGuard™ EPS) reach commercial profitability. Therefore, in order to fund the Company’s operations until such time that the Company can generate substantial revenues, the Company may need to raise additional funds. b. COVID-19 Pandemic During the year ended December 31, 2020, in an effort to contain and mitigate the spread of COVID-19, many countries have imposed unprecedented restrictions on travel, quarantines and other public health safety measures. As of the beginning of the second quarter of 2020, we began to experience a significant COVID-19 related impact on our financial condition and results of operations, which we primarily attribute to the postponement of CGuard EPS procedures (non-emergency procedures), as hospitals shifted resources to patients affected by COVID-19. To the best of our knowledge, most European countries in which we operate are reinstating elective procedures, but we do not know when the hospitals will resume to normal pre-pandemic levels with such procedures in light of recent increases in COVID-19 cases in the territories we sell into. We anticipate that the continuation of the pandemic and related restrictions and safety measures would likely result in a continued fluctuations in sales of our products for the upcoming periods.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Significant Accounting Policies	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations, assessing the likelihood of exercise of options to extend the lease term and legal contingencies. b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates. c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation. d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents. e. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable - Trade”. f. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value. The fair value of the Company’s financial instruments approximates their carrying values.” g. Leases In February 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. We adopted the new standard on January 1, 2019 using the modified retrospective transition method and we did not restate comparative periods. The new standard provides a number of optional practical expedients in transition. We have elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs for leases entered into prior to adoption of Topic 842. Additionally, the Company did not separate lease and non-lease components for all of our leases. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. Instead, we will continue to recognize the lease payments for those leases in profit or loss on a straight-line basis over the lease term. The new standard had a material effect on the Company’s financial statements. The most significant effects of adoption relate to (1) the recognition of new operating lease ROU assets and operating lease liabilities on its balance sheet for real estate operating leases; and (2) providing significant new disclosures about its leasing activities. Upon adoption, we recognized additional operating lease liabilities, of approximately $1.2 million based on the present value of the remaining lease payments under current leasing standards for existing operating leases. The Company also recognized corresponding ROU assets of approximately $1.2 million. Lease terms may include options to extend or terminate the lease when the Company is reasonably certain that the extension option will be exercised or termination option will not be exercised. For Operating Lease expense is recognized on a straight-line basis over the lease term. Our leases may include variable payments based on measures that include changes in price index which are expensed as incurred and presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments. The new standard also provides practical expedients for an entity’s ongoing accounting. See Note 5. h. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements. i. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows. j. Revenue recognition A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. This occurs when products are shipped. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 10. The Company recognizes revenue net of value added tax (VAT). k. Research and development costs Research and development costs are charged to the statement of operations as incurred. l. Share-based compensation The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”). Employee equity awards are classified as equity awards and accounted for using the grant-date fair value method. The Company determines compensation expense associated with Restricted Stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach. m. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses - net”. n. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments. o. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $163,000 and $262,000 for the years ended December 31, 2020 and 2019, respectively. p. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock by the weighted average number of shares of common stock outstanding during the period, including 922,720 and 151,884 weighted average shares of common stock issuable to holders of Series B Convertible Preferred Stock for the years ended December 31, 2020 and 2019, respectively, (since they are convertible based on passage of time) and 72,493 weighted average shares of common stock issuable to holders of unexercised Pre-Funded Warrants for the year ended December 31, 2019. The total number of shares of common stock related to outstanding options, warrants, restricted stock, restricted stock units, Series C Convertible Preferred Stock and placement agent units excluded from the calculations of diluted loss per share were 32,493,268 and 4,707,230 for the years ended December 31, 2020 and 2019, respectively. q. Segment reporting The Company has one operating and reportable segment. r. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. s. Issued accounting pronouncements effective in future periods Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company meets the definition of an SRC and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not believe the adoption of this standard will have a material impact on its consolidated financial statements.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	NOTE 3 - PROPERTY, PLANT AND EQUIPMENT a. Composition of assets, grouped by major classifications, is as follows: December 31, 2020 2019 ($ in thousands) Cost: Computer equipment $ 289 $ 287 Office furniture and equipment 95 95 Machinery and equipment 1,427 1,414 Leasehold improvements 211 206 2,022 2,002 Less - accumulated depreciation and amortization (1,574 ) (1,455 ) Net carrying amount $ 448 $ 547 b. Depreciation and amortization expenses totaled approximately $151,000 and $158,000 for the years ended December 31, 2020 and 2019, respectively.

Liability for Employees Right U

Liability for Employees Right Upon Retirement	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
Liability for Employees Right Upon Retirement	NOTE 4 - LIABILITY FOR EMPLOYEES RIGHT UPON RETIREMENT Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to section 14 of the Israeli Severance Compensation Act, 1963, some of the Company’s employees are entitled to have monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with section 14 relieve the Company from any future severance payments to these employees. The severance pay liability of the Company for the rest of its Israeli employees, which reflects the undiscounted amount of the liability, is based upon the number of years of service and the latest monthly salary. The severance pay liability is partly covered by insurance policies and by regular deposits with recognized severance payment funds. The Company may only withdraw funds previously deposited for savings in connection with the payment of severance. The severance pay expenses were approximately $276,000 and $197,000 for the years ended December 31, 2020 and 2019, respectively. Defined contribution plan expenses were approximately $339,000 and $294,000 for the years ended December 31, 2020 and 2019, respectively. The Company expects contribution plan expenses in 2021 to be approximately $346,000.

Lease Agreements

Lease Agreements	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Lease Agreements	NOTE 5 – LEASE AGREEMENTS 1) The Company’s Israeli subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2020 with an option to extend the agreement for two additional years until December 31, 2022 under the terms stipulated in the agreement. The company exercised the Option Period as estimated. In addition, the Company amended the agreement mentioned above which include a new option period for two additional years until December 31, 2024 under the terms stipulated in the agreement, the Option Period was taken in consideration when calculating the operating lease right of use assets and liabilities. In addition, the Company entered into another amendment to the lease agreement for a lease of additional space in the facility, the additional space amendment was taken in consideration when calculating the operating lease right of use assets and liabilities. 2) The Company leases its motor vehicles under operating lease agreements. 3) Operating lease cost for the year ended December 31, 2020 was comprised of the following: Twelve months ended December 31 Twelve months ended December 31 2020 2019 ($ in thousands) ($ in thousands) Operating lease expense 370 358 Short-term lease expense - 8 370 366 Supplemental information related to leases are as follows: December 31 December 31 2020 2019 ($ in thousands) ($ in thousands) Operating lease right-of-use assets 1,265 937 Current Operating lease liabilities (400 ) (362 ) Non-current operating lease liabilities (999 ) (653 ) Other information: Operating cash flows from operating leases (cash paid in thousands) (387 ) (366 ) Weighted Average Remaining Lease Term 1.73 1.33 Weighted Average Discount Rate 8.38 % 9.07 % Maturities of lease liabilities are as follows: Amount ($ in thousands) 2021 421 2022 389 2023 400 2024 419 Total lease payments 1,629 Less imputed interest (230 ) Total 1,399

Commitments and Contingent Liab

Commitments and Contingent Liabilities	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingent Liabilities	NOTE 6 - COMMITMENTS AND CONTINGENT LIABILITIES Litigation: In July 2016, a service provider filed a suit seeking damages from the Company’s subsidiary amounting to $1,967,822. The Company’s subsidiary and the plaintiff have entered into a confidential settlement agreement in the amount of $600,000, and on April 24, 2019, the parties filed a stipulation of dismissal, dismissing all claims in this action. On April 25, 2019, the court denied as moot all pending motions. The related increase in provision of $354,000 was recorded to “Research and development expense” within the Consolidated Statements of Operations for the year months ended December 31, 2019. In July 2019, a former distributor filed a suit seeking damages from the Company’s subsidiary for pre-paid goods subject to the voluntary field action (from April 2014) amounting to €1,830,000 (which is approximately $2.0 million), or alternatively €1,024,000 (which is approximately $1.1 million). In January 2021, we executed a Mediation Agreement with the former distributor, pursuant to which the former distributor agreed to release the Company from all claims stated in the Complaint in exchange for a payment of $580,000. Accordingly, the amount of $580,000 was recorded as a debit to revenue. On July 28, 2020, we entered into a settlement agreement and release with the prior underwriter, under which it provided us a final, unconditional release from any further obligations arising out of or related to the engagement agreements, underwriting agreements and placement agency agreements which we had been party to with it and with respect to any services which it had provided to us. We, in turn, provided the prior underwriter a final, unconditional release from any further obligations arising out of or related to the prior agreements and services. As consideration for the final release provided to us, we paid to the prior underwriter $400,000 in cash and reduced, to $0.495, the exercise price per share of warrants to purchase 274,029 shares of our common stock that had been issued by us to the prior underwriter in various offerings that took place between March 2018 and September 2019. That reduced exercise price represents the exercise price for the Series F Warrants that we issued in our June 2020 public offering. The warrants that were repriced had existing exercise prices per share ranging from $187.50 to $2.25 and a weighted average exercise price per share of $7.32. All other terms of those warrants will remain unchanged. The related increase in expenses of $400,000 was recorded to “General and Administrative expense” within the Consolidated Statements of Operations. In July 2020, a former senior employee of InspireMD GmbH filed a statement of claim at the Munich Labor Court, seeking confirmation of the court that the notice of termination is not effective. On November 10, 2020, we entered into a settlement agreement. As consideration for the final release, we paid the former senior employee 25,000 Eur (approximately $30,000) which was recorded to “Selling and marketing expense” within the Consolidated Statements of Operations.

Equity

Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Equity	NOTE 7 - EQUITY a. Share capital The Company’s common stock are listed on the NYSE American. On March 27, 2019, the Company filed with the Secretary of State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a one-for-fifty reverse stock split of its common stock, par value $0.0001 per share, effective as of March 29, 2019, which decreased the number of issued and outstanding shares of common stock and restricted stock as of December 31, 2018 from 38.4 million shares to 769 thousand shares. All related share and per share data have been retroactively applied to the financial statements and their related notes for all periods presented. Public Offering On April 8, 2019, the Company closed an underwritten public offering of 486,957 shares of the Company’s common stock at the offering price to the public of $5.00 per share. The Company received net proceeds of approximately $2 million from the offering, after deducting underwriter discounts and commissions and other fees and expenses payable by the Company. In connection with this public offering, on April 12, 2019, the underwriter partially exercised its over-allotment option and purchased an additional 12,393 shares of our common stock at a price to the public of $5.00 per share. The Company received net proceeds of approximately $47,000 from the exercise of the over-allotment option. In connection with the offering, the Company issued to the underwriter warrants to purchase up to 34,955 shares of common stock, or 7% of the shares sold in the offering, including the shares issued pursuant to the over-allotment option (the “April 2019 Underwriter Warrants”). The April 2019 Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending on April 4, 2024, at an exercise price of $6.25 per share (125% of the offering price to the public per share). Upon execution of the underwriting agreement, the respective conversion price of the outstanding shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock was reduced to $5.00 pursuant to the anti-dilution adjustment provisions of the Series B Convertible Preferred Stock and of the Series C Convertible Preferred Stock, and the number of shares of common stock issuable upon conversion of the Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock had increased as follows: ● an aggregate of 133,233 additional shares of common stock issuable upon conversion of the Series B Convertible Preferred Stock, including the payment of the cumulative dividends accrued thereunder in common stock, based on 17,303 shares of Series B Convertible Preferred Stock outstanding as of April 4, 2019. ● an aggregate of 50,708 additional shares of common stock issuable upon conversion of the Series C Convertible Preferred Stock, based on 59,423 shares of Series C Convertible Preferred Stock outstanding as of April 4, 2019. On September 19, 2019, the Company entered into an underwriting agreement relating to an underwritten public offering (the “September 2019 Offering”) of (i) 539,000 common units (“2019 Common Units”), with each 2019 Common Unit being comprised of one share of the Company’s common stock and one Series E warrant (collectively, the “Series E Warrants”) to purchase one share of common stock and (ii) 2,238,777 pre-funded units (“2019 Pre-Funded Units”), with each 2019 Pre-Funded Unit being comprised of one pre-funded warrant (collectively, the “2019 Pre-Funded Warrants”) to purchase one share of common stock and one Series E Warrant, which closed on September 24, 2019. The offering price to the public was $1.80 per 2019 Common Unit and $1.79 per 2019 Pre-Funded Unit. In connection with this public offering, on September 24, 2019, the underwriter partially exercised its over-allotment option and purchased an additional Series E Warrants to purchase 194,444 shares of common stock at a purchase price of $0.01 per Series E Warrant. The Series E Warrants included in the 2019 Common Units and the 2019 Pre-Funded Units are immediately exercisable at a price of $1.80 per share of common stock, subject to adjustment in certain circumstances, and expire five years from the date of issuance. Each 2019 Pre-Funded Warrant contained in a 2019 Pre-Funded Unit is exercisable for one share of our common stock at an exercise price of $0.01 per share. The 2019 Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the 2019 Pre-Funded Warrants are exercised in full. In connection with the offering, the Company issued to the underwriter warrants to purchase up to 194,444 shares of common stock, or 7% of the shares sold in the offering, including the number of shares of common stock issuable upon exercise of the 2019 Pre-Funded Warrants sold in the offering (the “September 2019 Underwriter Warrants”). The September 2019 Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending on September 19, 2024, at an exercise price of $2.25 per share (125% of the offering price to the public per 2019 Common Unit). Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s Series B Convertible Preferred Stock and Series C Preferred Stock, the conversion price of the outstanding shares of the Series B Convertible Preferred Stock and the Series C Preferred Stock was reduced to $1.80 per share, effective as of the date of the underwriting agreement entered for the September 2019 Offering, and the number of shares of common stock issuable upon conversion of the Series B Preferred Stock and the Series C Preferred Stock had increased as follows: ● an aggregate of 355,288 additional shares of common stock upon conversion of the Series B Preferred Stock and as payment of the dividends thereunder in common stock, based on 17,303 shares of Series B Preferred Stock outstanding as of September 19, 2019. ● an aggregate of 84,253 additional shares of common stock upon conversion of the Series C Preferred Stock, based on 37,025 shares of Series C Preferred Stock outstanding as of September 19, 2019. The Company received gross proceeds of $5.0 million from the offering, before deducting underwriter discounts and commissions and other fees and expenses payable by the Company. On June 5, 2020, the Company closed an underwritten public offering of (i) 7,635,800 units (“Units”), with each Unit being comprised of one share of the Company’s common stock, par value $0.0001 per share, and one Series F warrant (a “Series F Warrant”) to purchase one share of common stock, and (ii) 14,586,400 pre-funded units (the “Pre-Funded Units”), with each Pre-Funded Unit being comprised of one pre-funded warrant (a “Pre-Funded Warrant”) to purchase one share of common stock and one Series F Warrant. In connection with this public offering, the underwriter exercised its over-allotment option in full and purchased an additional 3,333,300 shares of common stock and 3,333,300 Series F Warrants. The offering price to the public was $0.45 per Unit and $0.449 per Pre-Funded Unit. The net proceeds to the Company from the offering and the exercise of the underwriter’s over-allotment option were approximately $10.7 million, after deducting underwriting discounts and commissions and payment of other estimated expenses associated with the offering, but excluding the proceeds, if any, from the exercise of Series F Warrants and the Pre-Funded Warrants sold in the offering. The pre-funded warrants exercisable at a price of $0.001 per share of common stock. The Series F Warrants included in the Common Units and the Pre-Funded Units are immediately exercisable at a price of $0.495 per share of common stock, subject to adjustment in certain circumstances, and expire June 2, 2025. The shares of common stock, or Pre-Funded Warrants in the case of the Pre-Funded Units, and the Series F Warrants were offered together, but the securities contained in the Common Units and the Pre-Funded Units were issued separately. During the year ended December 31, 2020, 2,866,600 Series F Warrants were converted into 2,866,600 shares of common stock. The net proceeds to the Company from exercise of the Series F Warrants were approximately $1.4 million. Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s Series B Convertible Preferred Stock and Series C Preferred Stock, the conversion price of the outstanding shares of the Series B Convertible Preferred Stock and the Series C Preferred Stock was reduced to $0.45 per share, effective as of the date of the underwriting agreement entered for the June 2020 Offering, and the number of shares of common stock issuable upon conversion of the Series B Preferred Stock and the Series C Preferred Stock had increased as follows: ● An aggregate of 1,665,414 additional shares of common stock upon conversion of the Series B Preferred Stock and as payment of the dividends thereunder in common stock, based on 17,303 shares of Series B Preferred Stock outstanding as of June 2, 2020. ● An aggregate of 283,285 additional shares of common stock upon conversion of the Series C Preferred Stock, based on 26,558 shares of Series C Preferred Stock outstanding as of June 2, 2020. for the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the Pre-funded Warrants have been included since the shares are issuable for a negligible consideration, as determined by the Company according to ASC 260-10-45-13, and have no vesting or other contingencies associated with them. The Company has also concluded that the series F warrants are classified as equity, since the warrants meet all criteria for equity classification. During the year ended December 31, 2020, the Company issued a total of 14,586,400 shares of common stock in connection with the exercise of all outstanding Pre-Funded Warrants issued in June 2020. In addition, the Company issued a total of 270,000 shares of its common stock in connection with the exercise of 270,000 Pre-Funded Warrants issued in September 2019. As of December 31, 2020, there are no outstanding Pre-Funded Warrants. During the year ended December 31, 2019, the Company issued a total of 2,000,811 shares of its common stock in connection with the exercise of an aggregate of 2,000,811 Pre-Funded Warrants and 2019 Pre-Funded Warrants. The Company received aggregate cash proceeds equal to approximately $35,705 in connection with such exercises. ATM Offering During the year ended December 31, 2020, the Company sold 12,917,448 shares of its common stock pursuant to its at-the-market (ATM) issuance sales agreement with A.G.P./Alliance Global Partners. These sales resulted in net proceeds to the Company of approximately $4,447 thousand. Pursuant to the full ratchet anti-dilution adjustment provisions in the respective certificate of designation for the Company’s Series B Convertible Preferred Stock and Series C Preferred Stock, the conversion price of the outstanding shares of the Series B Convertible Preferred Stock and the Series C Preferred Stock was reduced to $0.321 per share, triggered by the ATM Facility, effective as of December 14, 2020 , and the number of shares of common stock issuable upon conversion of the Series B Preferred Stock and the Series C Preferred Stock had increased as follows: ● an aggregate of 892,371 additional shares of common stock upon conversion of the Series B Preferred Stock and as payment of the dividends thereunder in common stock, based on 17,303 shares of Series B Preferred Stock outstanding as of December 14, 2020. ● an aggregate of 13,392 additional shares of common stock upon conversion of the Series C Preferred Stock, based on 2,343 shares of Series C Preferred Stock outstanding as of December 14, 2020. As of December 31, 2020, the Number of Preferred shares the amount each class is convertible into is below: Number of Preferred Stock Number of underlying Common stock Series B Convertible Preferred Stock* 17,303 3,112,923 ** Series C Convertible Preferred Stock 2,343 46,714 *** Total 3,159,637 * See “Note 11 - Subsequent events” regarding conversion of all remaining Series B Convertible Preferred Stock into common stock. ** On July 7, 2016, we issued 442,424 shares of Series B Preferred Stock in a public offering. Our Series B Preferred Stock has a stated value of $33.00 which currently converted into 3,112,923 reflecting a conversion price equal to $ 0.321. The holders of Series B Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversion price adjustment, if any. *** On March 14, 2017, we issued 1,069,822 shares of Series C Preferred Stock in a public offering. Our Series C Preferred Stock has a stated value of $6.40 which currently converted into 46,714 reflecting a conversion price equal to $ 0.321. As of December 31, 2020, the Company has outstanding warrants to purchase an aggregate of 26,705,502 shares of common stock as follows: Number of Weighted Series A Warrants 1,107 $ 8,750.00 Series B Warrants 2,448 $ 3,500.00 Series D Warrants 766,698 $ 15.00 Series E Warrants 2,972,221 $ 1.80 Series F Warrants 22,688,900 $ 0.50 Underwriter Warrants 274,029 $ 0.50 Other warrants 99 $ 21,993.00 Total Warrants 26,705,502 $ 1.82 As of December 31, 2020, the Company has 155,000,000 authorized shares of capital stock, par value $0.0001 per share, of which 150,000,000 are shares of common stock and 5,000,000 are shares of “blank check” preferred stock. In the event of our liquidation, dissolution, or winding up, holders of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are entitled to receive the amount of cash, securities or other property to which such holder would be entitled to receive with respect to such shares of Preferred Stock if such shares had been converted to common stock immediately prior to such event. b. Share-Based Compensation 1) Pursuant to the current Section 102 of the Israeli Tax Ordinance, which came into effect on January 1, 2003, options may be granted through a trustee (i.e., Approved 102 Options) or not through a trustee (i.e., Unapproved 102 Options). As a result of an election made by the Company under Section 102 of the Income Tax Ordinance, the Company will not be allowed to claim as an expense for tax purposes in Israel the amounts credited to the employee as capital gains to the grantees, although it will generally be entitled to do so in respect of the salary income component (if any) of such awards when the related tax is paid by the employee. 2) During the year ended December 31, 2020, the Company granted stock options to the CEO, employees and directors to purchase a total of 1,379,856 shares of the Company’s common stock. The options have exercise prices ranging from $0.33-$1.10 per share, respectively, which were the fair market value of the company’s common stock on the date of each respective grant. As of December 31, 2020, the fair value of the above options, using the Black-Scholes pricing models, was approximately $509,000. The options are subject to a three-year vesting period with one-third of such awards vesting each year. 3) During the years ended December 31, 2020 and 2019, the Company granted to the then CEO, employees and directors 2,781,920 and 70,582 restricted stock, respectively. The fair value of these restricted stock was approximately $1,051,604 and $668,000, respectively. The restricted stock are subject to a three-year vesting period, with one-third of such awards vesting each year. 4) During the years ended December 31, 2020 and 2019, the Company granted CEO and former CEO 1,357,668 and 165,000 Restricted Stock Units, respectively. The fair value of these restricted stock units was approximately $658,981 and $141,900, respectively. The restricted stock units granted during the years ended December 31, 2020 are subject to a three-year vesting period, with one-third of such awards vesting each year. The restricted stock units granted during the year ended December 31, 2019 were fully vested upon grant. 5) The following table summarizes information about stock options granted to employees: Year ended December 31 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 160 $ 189,161.99 164 $ 184,656 Granted 1,379,856 0.41 - - Forfeited (4,751 ) 343.51 (4 ) 4,423 Outstanding -end of period 1,375,265 $ 21.24 160 $ 189,162 Exercisable at the end of the period 115 $ 249,006 160 $ 189,162 6) The following table summarizes information about stock options granted to non-employees: Year ended December 31 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 16 $ 1,711,975 20 $ 1,693,174 Granted - - - - Forfeited (1 ) 2,156,208 (4 ) 1,617,338 Exercised - - - - Outstanding - end of period 15 1,682,385 16 1,711,975 Exercisable at the end of the period 15 1,682,385 16 1,711,975 7) The following table summarizes information about restricted stock granted to employees: Year ended December 31 2020 2019 Number of restricted stock Outstanding - beginning of period 69,631 19 Reverse Split Adjustments - (127 ) Granted 2,781,920 70,582 Forfeited (55,755 ) (838 ) Vested (9,915 ) (5 ) Outstanding - end of period 2,785,881 69,631 8) The following table summarizes information about Restricted Stock Unit granted to employees: Year ended December 31 2020 2019 Number of restricted stock Outstanding - beginning of period 165,000 - Granted 1,357,668 165,000 Forfeited - - Vested (165,000 ) - Outstanding - end of period 1,357,668 165,000 9) The following table provides additional information about all options outstanding and exercisable: Outstanding as of December 31, 2020 Exercise price Options outstanding Weighted average remaining contractual life (years) Options $0.175 2 1.39 2 $0.33-0.39 1,314,356 9.69 - $1.10 60,794 9.01 - $175 and above 128 4.71 128 1,375,280 9.66 130 The weighted average of the remaining contractual life of total vested and exercisable options as of December 31, 2020 was 4.66 years. The aggregate intrinsic value of the total exercisable options as of December 31, 2020 was approximately $1. The weighted average fair value of options granted was $0.37 for the year ended December 31, 2020. The weighted average fair value of options granted was estimated using the Black-Scholes option-pricing model. 10) The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2020: Year ended December 31 2020 Expected life 5.5-6.5 years Risk-free interest rates 0.32%-0.42 % Volatility 124.53%-136.66 % Dividend yield 0 % The Company does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term. Accordingly, as to ordinary course options granted, the expected term was determined using the simplified method, which takes into consideration the option’s contractual life and the vesting periods (for non-employees, the expected term is equal to the option’s contractual life). The annual risk-free rates are based on the yield rates of zero coupon non-index linked U.S. Federal Reserve treasury bonds as both the exercise price and the share price are in dollar terms. The Company’s expected volatility is derived from its historical data. 11) As of December 31, 2020, the total unrecognized compensation cost on employee and non-employee stock options and restricted stock, related to unvested stock-based compensation, amounted to approximately $1.7 million. This cost is expected to be recognized over a weighted-average period of approximately 0.95 years. This expected cost does not include the impact of any future stock-based compensation awards. 12) The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations: Year ended December 31 2020 2019 ($ in thousands) Cost of revenues $ 22 $ 14 Research and development 29 10 Sales and marketing 32 29 General and administrative 523 272 $ 606 $ 325

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Taxes On Income	NOTE 8 - TAXES ON INCOME: a. Tax laws applicable to the Company and its subsidiaries Taxation in the United States InspireMD, Inc. is taxed under U.S. tax laws. Accordingly, the applicable federal corporate tax rate in 2020 is 21%. State tax may also apply . Taxation in Israel The corporate tax rate was 23% in 2020 and will be 23% thereafter. Taxation in Germany InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825% and trade tax rate of 17.15%. b. Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Law”): InspireMD Ltd. has been granted a “Beneficiary Enterprises” status under the Investment Law including Amendment No. 60 thereof, which became effective in April 2005. The tax benefits derived from any such Beneficiary Enterprise relate only to taxable profits attributable to the specific program of investment to which the status was granted. The main benefit, to which InspireMD Ltd. is entitled, conditional upon the fulfilling of certain conditions stipulated by the above law, is a two-year exemption and five to eight years of a reduced tax rate of 10% to 23% from tax on income derived from beneficiary activities in facilities in Israel. The two-year exemption starts only when the Company starts to pay taxes after using all tax offsetting losses. The tax benefit period is twelve years from the year of election, which means that after a year of election, the two-year exemption and eight years of reduced tax rate can only be used within the next twelve years. The Company elected the year 2011 as a year of election. In the event of a distribution of tax-exempt income attributable to “Beneficiary Enterprises” as a cash dividend, the Company will be required to pay tax at a rate of 10% to 23% on the amount distributed, subject to certain conditions. In addition, dividends originating from income attributable to the “Beneficiary Enterprises” will be subject to a 20% withholding tax. Should InspireMD Ltd. derive income from sources other than the “Beneficiary Enterprises” during the period of benefits, such income shall be taxable at the regular corporate tax rate. 1) Conditions for entitlement to the benefits The entitlement to the above benefits is conditional upon InspireMD Ltd. fulfilling the conditions stipulated by the law, regulations published thereunder and the instruments of approval for the specific investments in approved assets. In the event of failure to comply with these conditions, the benefits may be cancelled, and InspireMD Ltd. may be required to refund the amount of the benefits, in whole or in part, with the addition of interest and linkage. The Company opted not to apply for Preferred Enterprise status (as defined in the Amendment of the Law for the Encouragement of Capital Investments, 1959). c. Carry forward tax losses As of December 31, 2020, the Company had a net carry forward tax loss of approximately $44 million, of which approximately $35 million (arising before January 1, 2018), expires until 2037, and approximately $9 million, which does not expire, but is limited to offset 80% of the net income in the year it is utilized. Under the U.S. tax laws, for net operating losses (NOLs) arising after December 31, 2017, the Tax Cuts and Jobs Act enacted on December 22, 2017 (the “2017 Act”) limits a taxpayer’s ability to utilize NOL carryforwards to 80% of taxable income. In addition, NOLs arising after 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before January 1, 2018, will not be subject to the foregoing taxable income limitation and will continue to have a two-year carryback and twenty-year carryforward period. Further to COVID-19 CARES act of the U.S. Treasury, the business tax provision temporarily removes the current law taxable income 80% limitation to allow an NOL to fully offset income in tax years 2018, 2019 and 2020. The provision also allows an NOL from tax years beginning in 2018, 2019, or 2020 to be carried back for five years. As of December 31, 2020, InspireMD Ltd., an Israeli subsidiary, had a net carry forward tax loss of approximately $98 million. Under Israeli tax laws, the carry forward tax losses can be utilized indefinitely. d. Loss before income taxes The components of loss before income taxes are as follows: Year ended December 31 2020 2019 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (3,897 ) $ (3,687 ) Subsidiaries (6,643 ) (6,329 ) $ (10,540 ) $ (10,016 ) e. Current taxes on income The main reconciling items between the statutory tax rate of the Company and the effective tax rate are the change in subsidiary tax rates and the change in valuation allowance in respect of tax benefits from carried forward tax losses due to uncertainty of the realization of such tax benefits and changes in tax rates following the 2017 Act. The changes in the valuation allowance for the year ended December 31, 2020 and 2019 were as follows: Year ended December 31 2020 2019 ($ in thousands) Balance at the beginning of the year $ 31,181 $ 27,640 Changes during the year: Losses during the year (including foreign exchange rate effect) 3,964 3,541 Balance at the end of the year $ 35,145 $ 31,181 f. Accounting for Uncertain Tax position Following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2020 and 2019 were as follows: Year ended December 31, 2020 2019 ($ in thousands) Balance at beginning of period $ 44 $ 28 Increase in uncertain tax positions because of tax positions taken during the year 8 16 Balance at end of period $ 52 $ 44 A summary of open tax years by major jurisdiction is presented below: Jurisdiction Years U.S. 2017-2020 Israel 2015-2020 Germany 2017-2020 United Kingdom 2014-2015 g. Deferred income tax: December 31, 2020 2019 ($ in thousands) Long-term: Allowance for bonus 2 57 Provision for vacation and recreation pay 63 35 R&D expenses 578 589 Operating lease right of use assets (291 ) (215 ) Operating lease liabilities 322 233 Share-based compensation 2,669 2,596 Carry forward tax losses 31,759 27,854 Accrued severance pay, net 43 32 35,145 31,181 Less-valuation allowance (35,145 ) (31,181 ) - -

Supplementary Financial Stateme

Supplementary Financial Statement Information	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplementary Financial Statement Information	NOTE 9 - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION: Balance sheets: Inventory: December 31, 2020 2019 ($ in thousands) Finished goods $ 350 $ 173 Work in process 376 81 Raw materials and supplies 689 982 $ 1,415 $ 1,236 a. Accounts payable and accruals-other: December 31, 2020 2019 ($ in thousands) Employees and employee institutions $ 1,236 $ 1,238 Accrued vacation and recreation pay 278 188 Accrued expenses 886 604 Accrual for settlement payment (see note 6) 580 - Current Operating lease liabilities 400 362 Other 89 77 $ 3,469 $ 2,469

Disaggregated Revenue and Entit

Disaggregated Revenue and Entity Wide Disclosures	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Disaggregated Revenue and Entity Wide Disclosures	NOTE 10 – DISAGGREGATED REVENUE AND ENTITY WIDE DISCLOSURES Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: Year ended December 31, 2020 2019 ($ in thousands) Germany $ 708 $ 727 Italy 596 686 Poland 219 370 Other (2020 - net of settlement payment of $580, see note 6) 962 1,938 $ 2,485 $ 3,721 By product: Year ended December 31, 2020 2019 ($ in thousands) CGuard™ EPS $ 2,764 $ 3,265 MGuard Prime™ EPS (2020 - net of settlement payment of $580, see note 6) (279 ) 456 $ 2,485 $ 3,721 By principal customers (2020 - before of settlement payment of $580 see note 6): Year ended December 31, 2020 2019 Customer A 21 % 18 % Customer B 11 % 8 % Customer C 8 % 10 % Customer D 7 % 10 % All tangible long lived assets are located in Israel.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 - SUBSEQUENT EVENTS: Subsequent to December 31, 2020 the Company had several stock transactions as follows (U.S. dollars in thousands, except share data): Common Stock Gross amount BALANCE as of December 31, 2020 49,264,830 Issuance of shares to Chinese distributor 1,341,682 900 (a) ATM sales 12,277,844 5,659 (b) February 2021 public offering 33,387,096 20,700 (c) Series F and Series G warrants exercise 18,381,177 9,469 (d) Conversion of Series B Convertible Preferred Stock to common shares 3,112,923 - (e) a. On February 3, 2021, the Company entered into a Distribution Agreement with three China-based partners, pursuant to which the Chinese partners will be responsible for conducting the necessary registration trials for commercial approval of the Company’s products in China, followed by an eight-year exclusive distribution right to sell the Company’s products in China with the term of the agreement continuing on a year-to-year basis unless terminated. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations. The Distribution Agreement may be terminated for cause upon failure to meet minimum purchase obligations, failure to obtain regulatory approvals or for other material breaches. In addition, and on the same day, the Company entered into an investment transaction with one of the Chinese parties to the Distribution Agreement, , which included (i) a Securities Purchase Agreement, or the SPA, pursuant to which investor agreed to invest $900,000 in exchange for shares of the Company’s common stock at a purchase price of $0.6708 per share. b. Subsequent to year-end, the Company sold an aggregate of 12,277,844 shares of common stock for aggregate gross proceeds of $5,659,000 under the ATM Sales Agreement. In addition, in January 2021 we received $323,000 for shares of common stock sold on December 2020 and recorded to "Receivable for sale of Shares" in current assets of the Consolidated Balance Sheet as of December 31, 2020. c. On February 3, 2021, the Company entered into an underwriting agreement with A.G.P./Alliance Global Partners, relating to an underwritten public offering (the “Offering”) of 29,032,258 units (“Units”), with each Unit being comprised of one share of the Company’s common stock, par value $0.0001 per share, and one Series G warrant to purchase one-half of one share of Common Stock. The offering price to the public was $0.62 per Unit. The Series G Warrants are immediately exercisable at a price of $0.682 per share, subject to adjustment in certain circumstances, and expire five years from the date of issuance. The Offering closed on February 8, 2021. The Company granted the Underwriter a 45-day option to purchase up to an additional 4,354,838 Units consisting of 4,354,838 shares of Common Stock and Series G Warrants to purchase 2,177,419 shares of common stock in the Offering, which the Underwriter exercised in full on February 4, 2021. The Company granted the Underwriter a compensation warrant to purchase up to 1,669,355 shares of Common Stock. The Underwriter Warrants have an exercise price of $0.682 per share and are exercisable immediately and for five years from the date of effectiveness of the registration statement in connection with the Offering. The net proceeds to the Company from the Offering, after giving effect to the exercise of the Underwriter’s over-allotment option, were approximately $18.9 million, after deducting underwriting discounts and commissions and payment of other estimated expenses associated with the Offering, but excluding the proceeds, if any, from the exercise of Series G Warrants sold in the Offering. d. Subsequent to year-end, Series F and Series G warrants to purchase shares of common stock were exercised by investors at an exercise price of $0.495 and $0.682 per share, resulting in the issuance of 18,381,177 shares of common stock for proceeds of approximately $9,469,000. e. On February 3, 2021, 17,303 shares of Series B Convertible Preferred Stock were converted into 3,112,923 shares of common stock.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Use of Estimates	a. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates using assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to inventory valuations, assessing the likelihood of exercise of options to extend the lease term and legal contingencies.
Functional Currency	b. Functional currency The currency of the primary economic environment in which the operations of the Company and its subsidiaries are conducted is the U.S. dollar (“$” or “dollar”). Accordingly, the functional currency of the Company and its subsidiaries is the U.S. dollar. The dollar figures are determined as follows: transactions and balances originally denominated in dollars are presented in their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. The resulting translation gains or losses are recorded as financial income or expense, as appropriate. For transactions reflected in the statements of operations in foreign currencies, the exchange rates at transaction dates are used. Depreciation and changes in inventories and other changes deriving from non-monetary items are based on historical exchange rates.
Principles of Consolidation	c. Principles of consolidation The consolidated financial statements include the accounts of the Company and of its subsidiaries. Intercompany transactions and balances have been eliminated upon consolidation.
Cash and Cash Equivalents	d. Cash and cash equivalents The Company considers all highly liquid investments, which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawal or use, to be cash equivalents.
Concentration of Credit Risk and Allowance for Doubtful Accounts	e. Concentration of credit risk and allowance for doubtful accounts Financial instruments that may potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, which are deposited in major financially sound institutions in the U.S, Israel and Germany, and trade accounts receivable. The Company’s trade accounts receivable is derived from revenues earned from customers from various countries. The Company performs ongoing credit evaluations of its customers’ financial condition and, requires no collateral from its customers. The Company also has a credit insurance policy for some of its customers. The Company maintains an allowance for doubtful accounts receivable based upon the expected ability to collect the accounts receivable. The Company reviews its allowance for doubtful accounts quarterly by assessing individual accounts receivable and all other balances based on historical collection experience and an economic risk assessment. If the Company determines that a specific customer is unable to meet its financial obligations to the Company, the Company provides an allowance for credit losses to reduce the receivable to the amount management reasonably believes will be collected, which is netted against “Accounts receivable - Trade”.
Inventory	f. Inventory Inventories are stated at the lower of cost (cost is determined on a “first-in, first-out” basis) or net realizable value. The Company’s inventories generally have a limited shelf life and are subject to impairment as they approach their expiration dates. The Company regularly evaluates the carrying value of its inventory and when, based on such evaluation, factors indicate that impairment has occurred, the Company impairs the inventories’ carrying value. The fair value of the Company’s financial instruments approximates their carrying values.”
Leases	g. Leases In February 2016, the FASB established ASC Topic 842, Leases (Topic 842), by issuing ASU No. 2016-02, which requires lessees to recognize leases on-balance sheet and disclose key information about leasing arrangements. The new standard establishes a right-of-use (ROU) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations. We adopted the new standard on January 1, 2019 using the modified retrospective transition method and we did not restate comparative periods. The new standard provides a number of optional practical expedients in transition. We have elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs for leases entered into prior to adoption of Topic 842. Additionally, the Company did not separate lease and non-lease components for all of our leases. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. Instead, we will continue to recognize the lease payments for those leases in profit or loss on a straight-line basis over the lease term. The new standard had a material effect on the Company’s financial statements. The most significant effects of adoption relate to (1) the recognition of new operating lease ROU assets and operating lease liabilities on its balance sheet for real estate operating leases; and (2) providing significant new disclosures about its leasing activities. Upon adoption, we recognized additional operating lease liabilities, of approximately $1.2 million based on the present value of the remaining lease payments under current leasing standards for existing operating leases. The Company also recognized corresponding ROU assets of approximately $1.2 million. Lease terms may include options to extend or terminate the lease when the Company is reasonably certain that the extension option will be exercised or termination option will not be exercised. Lease expense is recognized on a straight-line basis over the lease term. Our leases may include variable payments based on measures that include changes in price index which are expensed as incurred and presented as operating expense on the condensed consolidated statements of operations in the same line item as expense arising from fixed lease payments. The new standard also provides practical expedients for an entity’s ongoing accounting. See Note 5.
Property, Plant and Equipment	h. Property, plant and equipment Property, plant and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets: over three years for computers and other electronic equipment, and seven to fifteen years for office furniture and equipment and machinery and equipment (mainly seven years). Leasehold improvements are amortized on a straight-line basis over the term of the lease, which is shorter than the estimated life of the improvements.
Impairment in Value of Long-lived Assets	i. Impairment in value of long-lived assets The Company tests long-lived intangible and tangible assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment would be recognized, and the assets would be written down to their estimated fair values, based on expected future discounted cash flows.
Revenue Recognition	j. Revenue recognition A contract with a customer exists only when: 1) the parties to the contract have approved it and are committed to perform their respective obligations, 2) the Company can identify each party’s rights regarding the distinct goods or services to be transferred (“Performance Obligations”), 3) the Company can determine the transaction price for the goods or services to be transferred, 4) the contract has commercial substance and 5) it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for Performance Obligations upon transfer of control to the customer, excluding sales taxes. Revenue from sales of goods, including sales to distributors, is recognized when the customer obtains control of the product, once the Company has a present right to payment and the customer has legal title, and risk and rewards of ownership are obtained by the customer. This occurs when products are shipped. The Company recognizes the incremental costs of obtaining contracts as an expense since the amortization period of the assets that the Company otherwise would have recognized is one year or less. The costs are recorded under selling and marketing expenses. Disaggregated revenue is disclosed in Note 10. The Company recognizes revenue net of value added tax (VAT).
Research and Development Costs	k. Research and development costs Research and development costs are charged to the statement of operations as incurred.
Share-based Compensation	l. Share-based compensation The Company has equity incentive plans under which the Company grants equity awards, including stock options, restricted stock and restricted stock units (“RSUs”). Employee equity awards are classified as equity awards and accounted for using the grant-date fair value method. The Company determines compensation expense associated with Restricted Stock and RSUs based on the fair value of our common stock on the date of grant. The fair value of option awards is estimated using the Black-Scholes valuation model and expensed over the requisite service period. The Company elected to account for forfeitures as they occur. The Company elected to recognize compensation expenses for awards with only service conditions that have graded vesting schedules using the accelerated multiple option approach.
Uncertain Tax Positions	m. Uncertain tax positions The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. If under the first step a tax provision is assessed to be more likely than not of being sustained on audit, the second step is performed, under which the tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest related to unrecognized tax benefits within “Financial expenses - net”.
Deferred Income Taxes	n. Deferred income taxes Deferred taxes are determined utilizing the “asset and liability” method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws, and on tax rates anticipated to be in effect when the deferred taxes are expected to be paid or realized. The Company assesses realization of deferred income tax assets and, based on all available evidence, concludes whether it is more likely than not that the net deferred income tax assets will be realized. A valuation allowance is provided for the amount of deferred income tax assets not considered to be realizable. The Company may incur an additional tax liability in the event of intercompany dividend distributions by its subsidiaries. Such additional tax liability in respect of these foreign subsidiaries has not been provided for in these financial statements as it is the Company’s policy to permanently reinvest the subsidiaries’ earnings and to consider distributing dividends only in connection with a specific tax opportunity that may arise. Taxes that would apply in the event of disposal of investments in a foreign subsidiary have not been taken into account in computing the deferred taxes, as it is the Company’s intention to hold, and not to realize, these investments.
Advertising	o. Advertising Costs related to advertising and promotion of products are charged to sales and marketing expense as incurred. Advertising expenses were approximately $163,000 and $262,000 for the years ended December 31, 2020 and 2019, respectively.
Net Loss Per Share	p. Net loss per share Basic and diluted net loss per share is computed by dividing the net loss for the period attributable to common stock by the weighted average number of shares of common stock outstanding during the period, including 922,720 and 151,884 weighted average shares of common stock issuable to holders of Series B Convertible Preferred Stock for the years ended December 31, 2020 and 2019, respectively, (since they are convertible based on passage of time) and 72,493 weighted average shares of common stock issuable to holders of unexercised Pre-Funded Warrants for the year ended December 31, 2019. The total number of shares of common stock related to outstanding options, warrants, restricted stock, restricted stock units, Series C Convertible Preferred Stock and placement agent units excluded from the calculations of diluted loss per share were 32,493,268 and 4,707,230 for the years ended December 31, 2020 and 2019, respectively.
Segment Reporting	q. Segment reporting The Company has one operating and reportable segment.
Fair Value Measurement	r. Fair value measurement The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs not quoted on active markets but corroborated by market data. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.
Issued Accounting Pronouncements Effective in Future Periods	s. Issued accounting pronouncements effective in future periods Financial Instruments - Credit Losses In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments. This guidance replaces the current incurred loss impairment methodology. Under the new guidance, on initial recognition and at each reporting period, an entity is required to recognize an allowance that reflects its current estimate of credit losses expected to be incurred over the life of the financial instrument based on historical experience, current conditions and reasonable and supportable forecasts. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates (“ASU 2019-10”). The purpose of this amendment is to create a two-tier rollout of major updates, staggering the effective dates between larger public companies and all other entities. This granted certain classes of companies, including Smaller Reporting Companies (“SRCs”), additional time to implement major FASB standards, including ASU 2016-13. Larger public companies will have an effective date for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. All other entities are permitted to defer adoption of ASU 2016-13, and its related amendments, until the earlier of fiscal periods beginning after December 15, 2022. Under the current SEC definitions, the Company meets the definition of an SRC and is adopting the deferral period for ASU 2016-13. The guidance requires a modified retrospective transition approach through a cumulative-effect adjustment to retained earnings as of the beginning of the period of adoption. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements but does not believe the adoption of this standard will have a material impact on its consolidated financial statements.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property Plant and Equipment	a. Composition of assets, grouped by major classifications, is as follows: December 31, 2020 2019 ($ in thousands) Cost: Computer equipment $ 289 $ 287 Office furniture and equipment 95 95 Machinery and equipment 1,427 1,414 Leasehold improvements 211 206 2,022 2,002 Less - accumulated depreciation and amortization (1,574 ) (1,455 ) Net carrying amount $ 448 $ 547

Lease Agreements (Tables)

Lease Agreements (Tables)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Schedule of Operating Lease Cost	3) Operating lease cost for the year ended December 31, 2020 was comprised of the following: Twelve months ended December 31 Twelve months ended December 31 2020 2019 ($ in thousands) ($ in thousands) Operating lease expense 370 358 Short-term lease expense - 8 370 366
Schedule of Supplemental Information Related to Leases	Supplemental information related to leases are as follows: December 31 December 31 2020 2019 ($ in thousands) ($ in thousands) Operating lease right-of-use assets 1,265 937 Current Operating lease liabilities (400 ) (362 ) Non-current operating lease liabilities (999 ) (653 ) Other information: Operating cash flows from operating leases (cash paid in thousands) (387 ) (366 ) Weighted Average Remaining Lease Term 1.73 1.33 Weighted Average Discount Rate 8.38 % 9.07 %
Schedule of Maturities of Lease Liabilities	Maturities of lease liabilities are as follows: Amount ($ in thousands) 2021 421 2022 389 2023 400 2024 419 Total lease payments 1,629 Less imputed interest (230 ) Total 1,399

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Schedule of Convertible Preferred Shares	As of December 31, 2020, the Number of Preferred shares the amount each class is convertible into is below: Number of Preferred Stock Number of underlying Common stock Series B Convertible Preferred Stock* 17,303 3,112,923 ** Series C Convertible Preferred Stock 2,343 46,714 *** Total 3,159,637 * See “Note 11 - Subsequent events” regarding conversion of all remaining Series B Convertible Preferred Stock into common stock. ** On July 7, 2016, we issued 442,424 shares of Series B Preferred Stock in a public offering. Our Series B Preferred Stock has a stated value of $33.00 which currently converted into 3,112,923 reflecting a conversion price equal to $ 0.321. The holders of Series B Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company’s discretion, but excluding effect of future conversion price adjustment, if any. *** On March 14, 2017, we issued 1,069,822 shares of Series C Preferred Stock in a public offering. Our Series C Preferred Stock has a stated value of $6.40 which currently converted into 46,714 reflecting a conversion price equal to $ 0.321.
Schedule of Issuance of Warrants to Purchase Common Stock	As of December 31, 2020, the Company has outstanding warrants to purchase an aggregate of 26,705,502 shares of common stock as follows: Number of Weighted Series A Warrants 1,107 $ 8,750.00 Series B Warrants 2,448 $ 3,500.00 Series D Warrants 766,698 $ 15.00 Series E Warrants 2,972,221 $ 1.80 Series F Warrants 22,688,900 $ 0.50 Underwriter Warrants 274,029 $ 0.50 Other warrants 99 $ 21,993.00 Total Warrants 26,705,502 $ 1.82
Schedule of Stock Options Granted	5) The following table summarizes information about stock options granted to employees: Year ended December 31 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 160 $ 189,161.99 164 $ 184,656 Granted 1,379,856 0.41 - - Forfeited (4,751 ) 343.51 (4 ) 4,423 Outstanding -end of period 1,375,265 $ 21.24 160 $ 189,162 Exercisable at the end of the period 115 $ 249,006 160 $ 189,162 6) The following table summarizes information about stock options granted to non-employees: Year ended December 31 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding - beginning of period 16 $ 1,711,975 20 $ 1,693,174 Granted - - - - Forfeited (1 ) 2,156,208 (4 ) 1,617,338 Exercised - - - - Outstanding - end of period 15 1,682,385 16 1,711,975 Exercisable at the end of the period 15 1,682,385 16 1,711,975
Schedule of Restricted Stock Granted to Employees	7) The following table summarizes information about restricted stock granted to employees: Year ended December 31 2020 2019 Number of restricted stock Outstanding - beginning of period 69,631 19 Reverse Split Adjustments - (127 ) Granted 2,781,920 70,582 Forfeited (55,755 ) (838 ) Vested (9,915 ) (5 ) Outstanding - end of period 2,785,881 69,631
Schedule of Restricted Stock Unit Granted to Employees	8) The following table summarizes information about Restricted Stock Unit granted to employees: Year ended December 31 2020 2019 Number of restricted stock Outstanding - beginning of period 165,000 - Granted 1,357,668 165,000 Forfeited - - Vested (165,000 ) - Outstanding - end of period 1,357,668 165,000
Schedule of Additional Information About All Options Outstanding and Exercisable	9) The following table provides additional information about all options outstanding and exercisable: Outstanding as of December 31, 2020 Exercise price Options outstanding Weighted average remaining contractual life (years) Options $0.175 2 1.39 2 $0.33-0.39 1,314,356 9.69 - $1.10 60,794 9.01 - $175 and above 128 4.71 128 1,375,280 9.66 130
Schedule of Fair Value of Options Granted to Employees	10) The following table sets forth the assumptions that were used in determining the fair value of options granted to employees for the year December 31, 2020: Year ended December 31 2020 Expected life 5.5-6.5 years Risk-free interest rates 0.32%-0.42 % Volatility 124.53%-136.66 % Dividend yield 0 %
Schedule of Allocation of Total Share-based Compensation Expense	12) The following table summarizes the allocation of total share-based compensation expense in the consolidated statements of operations: Year ended December 31 2020 2019 ($ in thousands) Cost of revenues $ 22 $ 14 Research and development 29 10 Sales and marketing 32 29 General and administrative 523 272 $ 606 $ 325

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Components of Loss Before Income Taxes	The components of loss before income taxes are as follows: Year ended December 31 2020 2019 ($ in thousands) Loss before taxes on income: InspireMD, Inc. $ (3,897 ) $ (3,687 ) Subsidiaries (6,643 ) (6,329 ) $ (10,540 ) $ (10,016 )
Schedule of Changes in Valuation Allowance	The changes in the valuation allowance for the year ended December 31, 2020 and 2019 were as follows: Year ended December 31 2020 2019 ($ in thousands) Balance at the beginning of the year $ 31,181 $ 27,640 Changes during the year: Losses during the year (including foreign exchange rate effect) 3,964 3,541 Balance at the end of the year $ 35,145 $ 31,181
Schedule of Reconciliation of Uncertain Tax Positions	Following is a reconciliation of the total amounts of the Company’s uncertain tax positions during the year ended December 31, 2020 and 2019 were as follows: Year ended December 31, 2020 2019 ($ in thousands) Balance at beginning of period $ 44 $ 28 Increase in uncertain tax positions because of tax positions taken during the year 8 16 Balance at end of period $ 52 $ 44
Schedule of Open Tax Years by Major Jurisdiction	A summary of open tax years by major jurisdiction is presented below: Jurisdiction Years U.S. 2017-2020 Israel 2015-2020 Germany 2017-2020 United Kingdom 2014-2015
Schedule of Deferred Income Tax	December 31, 2020 2019 ($ in thousands) Long-term: Allowance for bonus 2 57 Provision for vacation and recreation pay 63 35 R&D expenses 578 589 Operating lease right of use assets (291 ) (215 ) Operating lease liabilities 322 233 Share-based compensation 2,669 2,596 Carry forward tax losses 31,759 27,854 Accrued severance pay, net 43 32 35,145 31,181 Less-valuation allowance (35,145 ) (31,181 ) - -

Supplementary Financial State_2

Supplementary Financial Statement Information (Tables)	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventories	Inventory: December 31, 2020 2019 ($ in thousands) Finished goods $ 350 $ 173 Work in process 376 81 Raw materials and supplies 689 982 $ 1,415 $ 1,236
Schedule of Accounts Payable and Accruals - Other	a. Accounts payable and accruals-other: December 31, 2020 2019 ($ in thousands) Employees and employee institutions $ 1,236 $ 1,238 Accrued vacation and recreation pay 278 188 Accrued expenses 886 604 Accrual for settlement payment (see note 6) 580 - Current Operating lease liabilities 400 362 Other 89 77 $ 3,469 $ 2,469

Disaggregated Revenue and Ent_2

Disaggregated Revenue and Entity Wide Disclosures (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Schedule of Revenues Attributed to Geographic Areas	Revenues are attributed to geographic areas based on the location of the customers. The following is a summary of revenues: Year ended December 31, 2020 2019 ($ in thousands) Germany $ 708 $ 727 Italy 596 686 Poland 219 370 Other (2020 - net of settlement payment of $580, see note 6) 962 1,938 $ 2,485 $ 3,721
Schedule of Revenues Attributed to Geographic Areas by Product	By product: Year ended December 31, 2020 2019 ($ in thousands) CGuard™ EPS $ 2,764 $ 3,265 MGuard Prime™ EPS (2020 - net of settlement payment of $580, see note 6) (279 ) 456 $ 2,485 $ 3,721
Schedule of Revenues Attributed to Geographic Areas by Principal Customers	By principal customers (2020 - before of settlement payment of $580 see note 6): Year ended December 31, 2020 2019 Customer A 21 % 18 % Customer B 11 % 8 % Customer C 8 % 10 % Customer D 7 % 10 %

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Schedule of Outstanding of Common Stock	Subsequent to December 31, 2020 the Company had several stock transactions as follows (U.S. dollars in thousands, except share data): Common Stock Gross amount BALANCE as of December 31, 2020 49,264,830 Issuance of shares to Chinese distributor 1,341,682 900 (a) ATM sales 12,277,844 5,659 (b) February 2021 public offering 33,387,096 20,700 (c) Series F and Series G warrants exercise 18,381,177 9,469 (d) Conversion of Series B Convertible Preferred Stock to common shares 3,112,923 - (e) a. On February 3, 2021, the Company entered into a Distribution Agreement with three China-based partners, pursuant to which the Chinese partners will be responsible for conducting the necessary registration trials for commercial approval of the Company’s products in China, followed by an eight-year exclusive distribution right to sell the Company’s products in China with the term of the agreement continuing on a year-to-year basis unless terminated. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations. The Distribution Agreement may be terminated for cause upon failure to meet minimum purchase obligations, failure to obtain regulatory approvals or for other material breaches. In addition, and on the same day, the Company entered into an investment transaction with one of the Chinese parties to the Distribution Agreement, , which included (i) a Securities Purchase Agreement, or the SPA, pursuant to which investor agreed to invest $900,000 in exchange for shares of the Company’s common stock at a purchase price of $0.6708 per share. b. Subsequent to year-end, the Company sold an aggregate of 12,277,844 shares of common stock for aggregate gross proceeds of $5,659,000 under the ATM Sales Agreement. In addition, in January 2021 we received $323,000 for shares of common stock sold on December 2020 and recorded to "Receivable for sale of Shares" in current assets of the Consolidated Balance Sheet as of December 31, 2020. c. On February 3, 2021, the Company entered into an underwriting agreement with A.G.P./Alliance Global Partners, relating to an underwritten public offering (the “Offering”) of 29,032,258 units (“Units”), with each Unit being comprised of one share of the Company’s common stock, par value $0.0001 per share, and one Series G warrant to purchase one-half of one share of Common Stock. The offering price to the public was $0.62 per Unit. The Series G Warrants are immediately exercisable at a price of $0.682 per share, subject to adjustment in certain circumstances, and expire five years from the date of issuance. The Offering closed on February 8, 2021. The Company granted the Underwriter a 45-day option to purchase up to an additional 4,354,838 Units consisting of 4,354,838 shares of Common Stock and Series G Warrants to purchase 2,177,419 shares of common stock in the Offering, which the Underwriter exercised in full on February 4, 2021. The Company granted the Underwriter a compensation warrant to purchase up to 1,669,355 shares of Common Stock. The Underwriter Warrants have an exercise price of $0.682 per share and are exercisable immediately and for five years from the date of effectiveness of the registration statement in connection with the Offering. The net proceeds to the Company from the Offering, after giving effect to the exercise of the Underwriter’s over-allotment option, were approximately $18.9 million, after deducting underwriting discounts and commissions and payment of other estimated expenses associated with the Offering, but excluding the proceeds, if any, from the exercise of Series G Warrants sold in the Offering. d. Subsequent to year-end, Series F and Series G warrants to purchase shares of common stock were exercised by investors at an exercise price of $0.495 and $0.682 per share, resulting in the issuance of 18,381,177 shares of common stock for proceeds of approximately $9,469,000. e. On February 3, 2021, 17,303 shares of Series B Convertible Preferred Stock were converted into 3,112,923 shares of common stock.

Significant Accounting Polici_3

Significant Accounting Policies (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)Segmentshares	Dec. 31, 2019USD ($)shares	Jan. 02, 2019USD ($)
Operating lease liabilities | $			$ 1,200
Right of use of asset | $	$ 1,265	$ 937	$ 1,200
Description of methodology used for computing depreciation	Straight-line method
Description of uncertain tax benefits	The tax benefit is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
Advertising expense | $	$ 163	$ 262
Weighted average shares common stock issuable	22,686,590	2,089,964
Number of operating segment | Segment	1
Number of reportable segment | Segment	1
Series B Convertible Preferred Stock [Member]
Weighted average shares common stock issuable	922,720	151,884
Series C Convertible Preferred Stock [Member]
Weighted average shares common stock issuable	32,493,268	4,707,230
Computers and Other Electronic Equipment [Member]
Estimated useful life	3 years
Machinery and Equipment [Member]
Estimated useful life	7 years
Pre-Funded Warrants [Member]
Weighted average shares common stock issuable		72,493
Minimum [Member] | Office Furniture and Equipment [Member]
Estimated useful life	7 years
Maximum [Member] | Office Furniture and Equipment [Member]
Estimated useful life	15 years

Property, Plant and Equipment_2

Property, Plant and Equipment (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation and amortization expenses	$ 151	$ 158

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property plant and equipment, gross	$ 2,022	$ 2,002
Less - accumulated depreciation and amortization	(1,574)	(1,455)
Net carrying amount	448	547
Computer Equipment [Member]
Property plant and equipment, gross	289	287
Office Furniture and Equipment [Member]
Property plant and equipment, gross	95	95
Machinery and Equipment [Member]
Property plant and equipment, gross	1,427	1,414
Leasehold Improvements [Member]
Property plant and equipment, gross	$ 211	$ 206

Liability for Employees Right_2

Liability for Employees Right Upon Retirement (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Percentage of monthly deposits on salary	8.33%
Severance expenses	$ 276	$ 197
Defined contribution plan expense	339	$ 294
2021 [Member]
Defined contribution plan expense estimated	$ 346

Lease Agreements (Details Narra

Lease Agreements (Details Narrative)	12 Months Ended
	Dec. 31, 2020
Lease expiration date	Dec. 31, 2020
Lease, description	The Company's Israeli subsidiary has a lease agreement for a facility in Israel, which expires on December 31, 2020 with an option to extend the agreement for two additional years until December 31, 2022 under the terms stipulated in the agreement.
Israeli Amendment Lease Agreement [Member]
Lease, description	The company exercised the Option Period as estimated. In addition, the Company amended the agreement mentioned above which include a new option period for two additional years until December 31, 2024 under the terms stipulated in the agreement.

Lease Agreements - Schedule of

Lease Agreements - Schedule of Operating Lease Cost (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease expense	$ 370	$ 358
Short-term lease expense		8
Total lease expenses	$ 370	$ 366

Lease Agreements - Schedule o_2

Lease Agreements - Schedule of Supplemental Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2019
Operating lease right-of-use assets	$ 1,265	$ 937	$ 1,200
Non-current operating lease liabilities	999	653
Operating cash flows from operating leases (cash paid in thousands)	$ (387)	$ (366)
Weighted Average Remaining Lease Term	1 year 8 months 23 days	1 year 3 months 29 days
Weighted Average Discount Rate	8.38%	9.07%
Operating Lease Liability [Member]
Current Operating lease liabilities	$ (400)	$ (362)

Lease Agreements - Schedule o_3

Lease Agreements - Schedule of Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Jan. 02, 2019
Total lease payments		$ 1,200
Operating Lease Liability [Member]
2021	$ 421
2022	389
2023	400
2024	419
Total lease payments	1,629
Less imputed interest	(230)
Total	$ 1,399

Commitments and Contingent Li_2

Commitments and Contingent Liabilities (Details Narrative) $ / shares in Units, € in Thousands, $ in Thousands	Jul. 28, 2020USD ($)$ / sharesshares	Jan. 31, 2021USD ($)	Jul. 31, 2020USD ($)	Jul. 31, 2020EUR (€)	Jul. 31, 2019USD ($)	Jul. 31, 2019EUR (€)	Jul. 31, 2016USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)
Payment for complaint								$ 580
Increase in provision for research and development expense									$ 354
Payments to prior underwriter	$ 400
Warrants exercise price | $ / shares	$ 0.495							$ 1.82
Warrants to purchase | shares	274,029							26,705,502
Weighted average exercise price | $ / shares	$ 7.32
Increase in provision for general and administrative expenses	$ 400
Selling and marketing expense								$ 2,103	$ 2,396
Minimum [Member]
Warrants exercise price | $ / shares	$ 187.50
Maximum [Member]
Warrants exercise price | $ / shares	$ 2.25
Confidential Settlement Agreement [Member]
Payment for complaint							$ 600
Settlement Agreement [Member] | Former Senior Employee [Member]
Selling and marketing expense			$ 30
Settlement Agreement [Member] | Euro [Member] | Former Senior Employee [Member]
Selling and marketing expense | €				€ 25
Service Provider [Member]
Law suit seeking damages							$ 1,967,822
Former Distributor [Member]
Law suit seeking damages					$ 2,000
Law suit seeking damages, description					In July 2019, a former distributor filed a suit seeking damages from the Company's subsidiary for pre-paid goods subject to the voluntary field action (from April 2014) amounting to €1,830,000 (which is approximately $2.0 million), or alternatively €1,024,000 (which is approximately $1.2 million).	In July 2019, a former distributor filed a suit seeking damages from the Company's subsidiary for pre-paid goods subject to the voluntary field action (from April 2014) amounting to €1,830,000 (which is approximately $2.0 million), or alternatively €1,024,000 (which is approximately $1.2 million).
Former Distributor [Member] | Alternatively [Member]
Law suit seeking damages					$ 1,100
Former Distributor [Member] | Euro [Member]
Law suit seeking damages | €						€ 1,830
Former Distributor [Member] | Euro [Member] | Alternatively [Member]
Law suit seeking damages | €						€ 1,024
Former Distributor [Member] | Mediation Agreement [Member] | Subsequent Event [Member]
Payment for complaint		$ 580

Equity (Details Narrative)

Equity (Details Narrative) - USD ($)		Jun. 05, 2020	Sep. 19, 2019	Apr. 12, 2019	Apr. 08, 2019	Mar. 27, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 14, 2020	Jul. 28, 2020	Jun. 02, 2020	Sep. 24, 2019	Apr. 04, 2019	Dec. 31, 2018
Reverse stock split						One-for-fifty reverse stock split of its common stock
Common stock, par value		$ 0.0001				$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares issued							49,264,830	3,916,134						38,400,000
Common stock, shares outstanding							49,264,830	3,916,134						38,400,000
Share price		$ 0.45
Number of warrants to purchase common stock							26,705,502			274,029
Warrants exercise price							$ 1.82			$ 0.495
Common units, shares		7,635,800
Common unit description		Each Unit being comprised of one share of the Company's common stock, par value $0.0001 per share, and one Series F warrant (a "Series F Warrant") to purchase one share of common stock.
Shares issued during the period new issue value								$ 6,335,000
Pre-funded warrants, shares								270,000
Outstanding pre-funded warrants are exercisable into shares of common stock
Proceeds from exercise of warrants							$ 16,395,000	$ 6,335,000
Capital stock shares authorized							155,000,000
Capital stock par value							$ 0.0001
Common stock shares authorized							150,000,000	150,000,000
Minimum [Member]
Warrants exercise price										187.50
Maximum [Member]
Warrants exercise price										$ 2.25
Stock Options [Member]
Stock option granted							1,379,856
Fair value of stock options							$ 509,000
Stock option vesting period							3 years
Stock Options [Member] | Minimum [Member]
Stock option granted, exercise price							$ 0.33
Stock Options [Member] | Maximum [Member]
Stock option granted, exercise price							$ 1.10
Restricted Stock [Member]
Stock granted							2,781,920	70,582
Fair value of restricted shares							$ 1,051,604	$ 668,000
Stock vesting period							3 years
Weighted average of the remaining contractual life of vested and exercisable options							4 years 7 months 28 days
Aggregate intrinsic value of exercisable options							$ 1
Weighted average fair value of options granted							$ 0.37
Restricted Stock Units (RSUs) [Member]
Stock granted							1,357,668	165,000
Stock vesting period							3 years
Fair value of restricted stock units							$ 658,981	$ 141,900
Employee and Non-employee Stock Options [Member]
Unvested stock-based compensation							$ 1,700,000
Unvested stock-based compensation weighted-average period for recognition							11 months 12 days
Common Stock [Member]
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of issuance costs, shares								3,039,161
Shares issued during the period new issue value	[1]
Over allotment shares		3,333,300
Shares outstanding							49,264,830	3,916,134						768,615
Warrant [Member]
Warrants outstanding							26,705,502
Preferred Stock Blank Check [Member]
Preferred stock shares authorized							5,000,000
Pre-Funded Units [Member]
Share price		$ 0.449
Common units, shares		14,586,400
Common unit description		Each Pre-Funded Unit being comprised of one pre-funded warrant (a "Pre-Funded Warrant") to purchase one share of common stock and one Series F Warrant.
Pre-Funded Warrants [Member]
Number of shares issued for exercise of warrants							14,586,400
Series B Convertible Preferred Stock [Member]
Shares of common stock issuable upon conversion			355,288										133,233
Preferred stock, shares outstanding			17,303										17,303
Series C Convertible Preferred Stock One [Member]
Shares of common stock issuable upon conversion			84,253										50,708
Preferred stock, shares outstanding			37,025										59,423
Underwriter Warrants [Member]
Number of warrants to purchase common stock							274,029
Warrants exercise price							$ 0.50
Series F Warrants [Member]
Common stock, par value		$ 0.0001
Share price		$ 0.45
Number of warrants to purchase common stock		1					22,688,900
Warrants exercise price							$ 0.50
Common units, shares		7,635,800
Over allotment shares		3,333,300
Proceeds from exercise of warrants		$ 10,700,000					$ 1,400,000
Conversion of converted shares							2,866,600
Series F Warrants [Member] | Pre-Funded Units [Member]
Warrants exercise price		$ 0.495
Warrants expiration date		Jun. 2, 2025
Preferred B Shares [Member]
Share price							$ 0.45
Preferred stock, shares outstanding							17,303	17,303
Additional shares of common stock									892,371		1,665,414
Shares outstanding									17,303		17,303
Preferred stock shares authorized							500,000	500,000
Preferred C Shares [Member]
Share price							$ 0.45
Preferred stock, shares outstanding							2,343	34,370
Additional shares of common stock									13,392		283,285
Shares outstanding									2,343		26,558
Preferred stock shares authorized							1,172,000	1,172,000
2019 Pre-Funded Units and Pre-Funded Warrants [Member]
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of issuance costs, shares								2,000,811
Number of warrants to purchase common stock								2,000,811
Shares issued during the period new issue value								$ 35,705
April 2019 Underwriter Warrants [Member]
Number of warrants to purchase common stock					34,955
Sale of stock, offering percentage					7.00%
Warrants exercise price					$ 6.25
Percentage for gross proceeds of offering					125.00%
Underwritten Public Offering [Member]
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of issuance costs, shares					486,957
Gross proceeds from offering					$ 2,000,000
Share price					$ 5
Over-Allotment Option [Member]
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of issuance costs, shares				12,393
Gross proceeds from offering				$ 47,000
Share price				$ 5
Over-Allotment Option [Member] | Series E Warrant [Member]
Number of warrants to purchase common stock												194,444
Warrants exercise price												$ 0.01
September 2019 Offering [Member]
Share price			$ 1.80
Common units, shares			539,000
Common unit description			Each 2019 Common Unit being comprised of one share of the Company's common stock and one Series E warrant (collectively, the "Series E Warrants") to purchase one share of common stock.
September 2019 Offering [Member] | Series E Warrant [Member]
Warrants exercise price			$ 1.80
September 2019 Offering [Member] | 2019 Pre-Fund Units [Member]
Share price			1.79
Warrants exercise price			$ 0.01
Common units, shares			2,238,777
Common unit description			Each 2019 Pre-Funded Unit being comprised of one pre-funded warrant (collectively, the "2019 Pre-Funded Warrants") to purchase one share of common stock and one Series E Warrant.
September 2019 Offering [Member] | Underwriter Warrants [Member]
Number of warrants to purchase common stock			194,444
Sale of stock, offering percentage			7.00%
Warrants exercise price			$ 0.01
Percentage for gross proceeds of offering			125.00%
Pre-fund warrants description			The September 2019 Underwriter Warrants are exercisable at any time and from time to time, in whole or in part, following the date of issuance and ending on September 19, 2024, at an exercise price of $2.25 per share (125% of the offering price to the public per 2019 Common Unit).
Proceeds from sale of stock			$ 5,000,000
At The Market Offering [Member] | Common Stock [Member]
Issuance of common shares, warrants, pre-funded warrants and exercise of pre-funded warrants, net of issuance costs, shares							12,917,448
Net proceeds from issuance of stock							$ 4,447,000
Secretary of State of Delaware a Certificate of Amendment [Member]
Common stock, shares issued						769,000
Common stock, shares outstanding						769,000
[1]	Represents an amount less than $1

Equity - Schedule of Convertibl

Equity - Schedule of Convertible Preferred Shares (Details)	12 Months Ended
	Dec. 31, 2020shares
Class of Stock [Line Items]
Number of underlying Common Stock	3,159,637
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of Preferred Stock	17,303	[1]
Number of underlying Common Stock	3,112,923	[2]
Series C Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of Preferred Stock	2,343
Number of underlying Common Stock	46,714	[3]
[1]	See "Note 11 - Subsequent events" regarding conversion of all remaining Series B Convertible Preferred Stock into common stock.
[2]	On July 7, 2016, we issued 442,424 shares of Series B Preferred Stock in a public offering. Our Series B Preferred Stock has a stated value of $33.00 which currently converted into 3,112,923 reflecting a conversion price equal to $ 0.321. The holders of Series B Preferred Stock are entitled to receive as cumulative dividends at the rate per share of 15% per annum of the stated value for five years, payable in cash or common stock, at the Company's discretion, but excluding effect of future conversion price adjustment, if any.
[3]	On March 14, 2017, we issued 1,069,822 shares of Series C Preferred Stock in a public offering. Our Series C Preferred Stock has a stated value of $6.40 which currently converted into 46,714 reflecting a conversion price equal to $ 0.321.

Equity - Schedule of Converti_2

Equity - Schedule of Convertible Preferred Shares (Details) (Parenthetical) - $ / shares	Mar. 14, 2017	Jul. 07, 2016	Dec. 31, 2020	Jun. 05, 2020
Stated value of stock issued				$ 0.45
Series B Preferred Stock [Member]
Stated value of stock issued			$ 0.45
Series B Preferred Stock [Member] | Public Offering [Member]
Number of stocks issued		442,424
Stated value of stock issued		$ 33
Number of preferred stock converted		3,112,923
Preferred stock conversion price		$ 0.321
Cumulative dividend rate		15.00%
Preferred C Shares [Member]
Stated value of stock issued			$ 0.45
Preferred C Shares [Member] | Public Offering [Member]
Number of stocks issued	1,069,822
Stated value of stock issued	$ 6.40
Number of preferred stock converted	46,714
Preferred stock conversion price	$ 0.321

Equity - Schedule of Issuance o

Equity - Schedule of Issuance of Warrants to Purchase Common Stock (Details) - $ / shares	Dec. 31, 2020	Jul. 28, 2020	Jun. 05, 2020
Class of Warrant or Right [Line Items]
Total Warrants	26,705,502	274,029
Weighted average exercise price	$ 1.82	$ 0.495
Series A Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants	1,107
Weighted average exercise price	$ 8,750
Series B Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants	2,448
Weighted average exercise price	$ 3,500
Series D Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants	766,698
Weighted average exercise price	$ 15
Series E Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants	2,972,221
Weighted average exercise price	$ 1.80
Series F Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants	22,688,900		1
Weighted average exercise price	$ 0.50
Underwriter Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants	274,029
Weighted average exercise price	$ 0.50
Other Warrants [Member]
Class of Warrant or Right [Line Items]
Total Warrants	99
Weighted average exercise price	$ 21,993

Equity - Schedule of Stock Opti

Equity - Schedule of Stock Options Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee [Member]
Class of Warrant or Right [Line Items]
Number of options Outstanding - beginning of period	160	164
Number of options Outstanding, Granted	1,379,856
Number of options Outstanding, Forfeited	(4,751)	(4)
Number of options Outstanding, Outstanding -end of period	1,375,265	160
Number of options Outstanding, Exercisable at the end of the period	115	160
Weighted average exercise price Outstanding - beginning of period	$ 189,162	$ 184,656
Weighted average exercise price, Granted	0.41
Weighted average exercise price, Forfeited	343.51	4,423
Weighted average exercise price, Outstanding -end of period	21.24	189,162
Weighted average exercise price, Exercisable at the end of the period	$ 249,006	$ 189,162
Non-Employee [Member]
Class of Warrant or Right [Line Items]
Number of options Outstanding - beginning of period	16	20
Number of options Outstanding, Granted
Number of options Outstanding, Forfeited	(1)	(4)
Number of options Outstanding, Exercised
Number of options Outstanding, Outstanding -end of period	15	16
Number of options Outstanding, Exercisable at the end of the period	15	16
Weighted average exercise price Outstanding - beginning of period	$ 1,711,975	$ 1,693,174
Weighted average exercise price, Granted
Weighted average exercise price, Forfeited	2,156,208	1,617,338
Weighted average exercise price, Exercised
Weighted average exercise price, Outstanding -end of period	1,682,385	1,711,975
Weighted average exercise price, Exercisable at the end of the period	$ 1,682,385	$ 1,711,975

Equity - Schedule of Restricted

Equity - Schedule of Restricted Stock Granted to Employees (Details) - Restricted Stock [Member] - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Number of restricted stock, Granted	2,781,920	70,582
Employee [Member]
Class of Warrant or Right [Line Items]
Number of restricted stock, Outstanding - beginning of period	69,631	19
Number of restricted stock, Reverse Split Adjustments		(127)
Number of restricted stock, Granted	2,781,920	70,582
Number of restricted stock, Forfeited	(55,755)	(838)
Number of restricted stock, Vested	(9,915)	(5)
Number of restricted stock, Outstanding - end of period	2,785,881	69,631

Equity - Schedule of Restrict_2

Equity - Schedule of Restricted Stock Unit Granted to Employees (Details) - Restricted Stock Units [Member] - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Number of restricted stock, Granted	1,357,668	165,000
Employee [Member]
Class of Warrant or Right [Line Items]
Number of restricted stock, Outstanding - beginning of period	165,000
Number of restricted stock, Granted	1,357,668	165,000
Number of restricted stock, Forfeited
Number of restricted stock, Vested	(165,000)
Number of restricted stock, Outstanding - end of period	1,357,668	165,000

Equity - Schedule of Additional

Equity - Schedule of Additional Information About All Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 1,375,280
Weighted average remaining contractual life (years)	9 years 7 months 28 days
Options exercisable	130
Exercise Price [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 0.175
Options outstanding	2
Weighted average remaining contractual life (years)	1 year 4 months 20 days
Options exercisable	2
Exercise Price One [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 0.39
Exercise price lower range | $ / shares	$ 0.33
Options outstanding	1,314,356
Weighted average remaining contractual life (years)	9 years 8 months 9 days
Options exercisable
Exercise Price Two [Member]
Class of Warrant or Right [Line Items]
Exercise price | $ / shares	$ 1.10
Options outstanding	60,794
Weighted average remaining contractual life (years)	9 years 4 days
Options exercisable
Exercise Price Three [Member]
Class of Warrant or Right [Line Items]
Exercise price, description	175 and above
Options outstanding	128
Weighted average remaining contractual life (years)	4 years 8 months 16 days
Options exercisable	128

Equity - Schedule of Fair Value

Equity - Schedule of Fair Value of Options Granted to Employees (Details)	12 Months Ended
	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Risk-free interest rate, minimum	0.32%
Risk-free interest rate, maximum	0.42%
Volatility, minimum	124.53%
Volatility, maximum	136.66%
Dividend yield	0.00%
Minimum [Member]
Class of Warrant or Right [Line Items]
Expected life	5 years 6 months
Maximum [Member]
Class of Warrant or Right [Line Items]
Expected life	6 years 6 months

Equity - Schedule of Allocation

Equity - Schedule of Allocation of Total Share-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right [Line Items]
Total share-based compensation expense	$ 606	$ 325
Cost of Sales [Member]
Class of Warrant or Right [Line Items]
Total share-based compensation expense	22	14
Research and Development [Member]
Class of Warrant or Right [Line Items]
Total share-based compensation expense	29	10
Sales and Marketing [Member]
Class of Warrant or Right [Line Items]
Total share-based compensation expense	32	29
General and Administrative [Member]
Class of Warrant or Right [Line Items]
Total share-based compensation expense	$ 523	$ 272

Taxes on Income (Details Narrat

Taxes on Income (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Federal corporate tax rate	21.00%
Tax rate on income of beneficiary enterprises	20.00%
Net carry forward tax loss	$ 44,000			$ 35,000
Operating loss carryforwards expiration period	5 years
Net loss carryforwards percentage	80.00%	80.00%	80.00%
Arising Before January 1, 2018 [Member]
Operating loss carryforwards expiration description	Expires until 2037
Limited [Member]
Net carry forward tax loss	$ 9,000
Israel Tax Authority [Member]
Federal corporate tax rate	23.00%
Revised tax rate on income of preferred enterprises		10.00%
Tax rate on income of beneficiary enterprises		23.00%
Income tax rate description	Upon the fulfilling of certain conditions stipulated by the above law, is a two-year exemption and five to eight years of a reduced tax rate of 10% to 23% from tax on income derived from beneficiary activities in facilities in Israel. The two-year exemption starts only when the Company starts to pay taxes after using all tax offsetting losses. The tax benefit period is twelve years from the year of election, which means that after a year of election, the two-year exemption and eight years of reduced tax rate can only be used within the next twelve years. The Company elected the year 2007, as a year of election and 2011 as an additional year of election.
Net carry forward tax loss	$ 98,000
Israel Tax Authority [Member] | 2020 and Thereafter [Member]
Federal corporate tax rate	23.00%
Germany [Member]
Federal corporate tax rate	15.825%
Corporate trade tax rate	17.15%

Taxes on Income - Schedule of C

Taxes on Income - Schedule of Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Loss before taxes on income	$ (10,540)	$ (10,016)
Parent Company [Member]
Loss before taxes on income	(3,897)	(3,687)
Subsidiaries [Member]
Loss before taxes on income	$ (6,643)	$ (6,329)

Taxes on Income - Schedule of_2

Taxes on Income - Schedule of Changes in Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 31,181	$ 27,640
Changes during the year: Losses during the year (including foreign exchange rate effect)	3,964	3,541
Balance at the end of the year	$ 35,145	$ 31,181

Taxes on Income - Schedule of R

Taxes on Income - Schedule of Reconciliation of Uncertain Tax Positions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Uncertain tax positions balance at beginning of period	$ 44	$ 28
Increase in uncertain tax positions because of tax positions taken during the year	8	16
Uncertain tax positions balance at end of period	$ 52	$ 44

Taxes on Income - Schedule of O

Taxes on Income - Schedule of Open Tax Years by Major Jurisdiction (Details)	12 Months Ended
	Dec. 31, 2020
U.S. [Member] | Earliest Tax Year [Member]
Open Tax Year	2017
U.S. [Member] | Latest Tax Year [Member]
Open Tax Year	2020
Israel [Member] | Earliest Tax Year [Member]
Open Tax Year	2015
Israel [Member] | Latest Tax Year [Member]
Open Tax Year	2020
Germany [Member] | Earliest Tax Year [Member]
Open Tax Year	2017
Germany [Member] | Latest Tax Year [Member]
Open Tax Year	2020
United Kingdom [Member] | Earliest Tax Year [Member]
Open Tax Year	2014
United Kingdom [Member] | Latest Tax Year [Member]
Open Tax Year	2015

Taxes on Income - Schedule of D

Taxes on Income - Schedule of Deferred Income Tax (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Allowance for bonus	$ 2	$ 57
Provision for vacation and recreation pay	63	35
R&D expenses	578	589
Operating lease right of use assets	(291)	(215)
Operating lease liabilities	322	233
Share-based compensation	2,669	2,596
Carry forward tax losses	31,759	27,854
Accrued severance pay, net	43	32
Deferred tax assets noncurrent	35,145	31,181
Less-valuation allowance	(35,145)	(31,181)	$ (27,640)
Deferred tax assets

Supplementary Financial State_3

Supplementary Financial Statement Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Finished goods	$ 350	$ 173
Work in process	376	81
Raw materials and supplies	689	982
Total inventories	$ 1,415	$ 1,236

Supplementary Financial State_4

Supplementary Financial Statement Information - Schedule of Accounts Payable and Accruals - Other (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Employees and employee institutions	$ 1,236	$ 1,238
Accrued vacation and recreation pay	278	188
Accrued expenses	886	604
Accrual for settlement payment (see note 6)	580
Current operating lease liabilities	400	362
Other	89	77
Accounts payable and accruals - other	$ 3,469	$ 2,469

Disaggregated Revenue and Ent_3

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues	$ 2,485	$ 3,721
Germany [Member]
Revenues	708	727
Italy [Member]
Revenues	596	686
Poland [Member]
Revenues	219	370
Other [Member]
Revenues	$ 962	$ 1,938

Disaggregated Revenue and Ent_4

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas (Details) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Other [Member]
Net of settlement	$ 580

Disaggregated Revenue and Ent_5

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas by Product (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Segment Reporting Information [Line Items]
Revenue	$ 2,485	$ 3,721
CGuard EPS [Member]
Segment Reporting Information [Line Items]
Revenue	2,764	3,265
MGuard Prime EPS [Member]
Segment Reporting Information [Line Items]
Revenue	$ (279)	$ 456

Disaggregated Revenue and Ent_6

Disaggregated Revenue and Entity Wide Disclosures - Schedule of Revenues Attributed to Geographic Areas by Principal Customers (Details) - Sales [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Customer A [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	21.00%	18.00%
Customer B [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	11.00%	8.00%
Customer C [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	8.00%	10.00%
Customer D [Member]
Segment Reporting Information [Line Items]
Percentage of revenues per major customer	7.00%	10.00%

Subsequent Events - Schedule of

Subsequent Events - Schedule of Outstanding Common Stock (Details) - USD ($) $ in Thousands		2 Months Ended	12 Months Ended
		Mar. 04, 2021	Dec. 31, 2020		Dec. 31, 2019
Balance			$ 5,383		$ 8,763
February 2021 public offering					6,335
Conversion of Series B Convertible Preferred Stock to common shares				[1]		[2]
Balance			12,163		5,383
Common Stock [Member]
Balance	[1]
Balance, shares			3,916,134		768,615
February 2021 public offering, shares					3,039,161
February 2021 public offering	[1]
Conversion of Series B Convertible Preferred Stock to common shares, shares			372,173		38,614
Conversion of Series B Convertible Preferred Stock to common shares	[1]
Balance	[1]		$ 5
Balance, shares			49,264,830		3,916,134
Subsequent Event [Member] | Common Stock [Member]
Balance
Balance, shares		49,264,830
Issuance of shares to Chinese distributor, shares	[3]	1,341,682
Issuance of shares to Chinese distributor	[3]	$ 900
ATM sales, shares	[4]	12,277,844
ATM sales	[4]	$ 5,659
February 2021 public offering, shares	[5]	33,387,096
February 2021 public offering	[5]	$ 20,700
Series F and Series G warrants exercise, shares	[6]	18,381,177
Series F and Series G warrants exercise	[6]	$ 9,469
Conversion of Series B Convertible Preferred Stock to common shares, shares	[7]	3,112,923
Conversion of Series B Convertible Preferred Stock to common shares	[7]
Balance		$ 36,728
Balance, shares		117,832,226
[1]	Represents an amount less than $1
[2]	Represents an amount less than $1 thousand
[3]	On February 3, 2021, the Company entered into a Distribution Agreement with three China-based partners, pursuant to which the Chinese partners will be responsible for conducting the necessary registration trials for commercial approval of the Company's products in China, followed by an eight-year exclusive distribution right to sell the Company's products in China with the term of the agreement continuing on a year-to-year basis unless terminated. Under the Distribution Agreement, the China-based partners will be subject to minimum purchase obligations. The Distribution Agreement may be terminated for cause upon failure to meet minimum purchase obligations, failure to obtain regulatory approvals or for other material breaches. In addition, and on the same day, the Company entered into an investment transaction with one of the Chinese parties to the Distribution Agreement, which included (i) a Securities Purchase Agreement, or the SPA, pursuant to which investor agreed to invest $900,000 in exchange for shares of the Company's common stock at a purchase price of $0.6708 per share.
[4]	Subsequent to year-end, the Company sold an aggregate of 12,277,844 shares of common stock for aggregate gross proceeds of $5,659,000 under the ATM Sales Agreement. In addition, in January 2021 we received $323,000 for shares of common stock sold on December 2020 and recorded to "Receivable for sale of Shares" in current assets of the Consolidated Balance Sheet as of December 31, 2020.
[5]	On February 3, 2021, the Company entered into an underwriting agreement with A.G.P./Alliance Global Partners, relating to an underwritten public offering (the "Offering") of 29,032,258 units ("Units"), with each Unit being comprised of one share of the Company's common stock, par value $0.0001 per share, and one Series G warrant to purchase one-half of one share of Common Stock. The offering price to the public was $0.62 per Unit. The Series G Warrants are immediately exercisable at a price of $0.682 per share, subject to adjustment in certain circumstances, and expire five years from the date of issuance. The Offering closed on February 8, 2021. The Company granted the Underwriter a 45-day option to purchase up to an additional 4,354,838 Units consisting of 4,354,838 shares of Common Stock and Series G Warrants to purchase 2,177,419 shares of common stock in the Offering, which the Underwriter exercised in full on February 4, 2021. The Company granted the Underwriter a compensation warrant to purchase up to 1,669,355 shares of Common Stock. The Underwriter Warrants have an exercise price of $0.682 per share and are exercisable immediately and for five years from the date of effectiveness of the registration statement in connection with the Offering. The net proceeds to the Company from the Offering, after giving effect to the exercise of the Underwriter's over-allotment option, were approximately $18.9 million, after deducting underwriting discounts and commissions and payment of other estimated expenses associated with the Offering, but excluding the proceeds, if any, from the exercise of Series G Warrants sold in the Offering.
[6]	Subsequent to year-end, Series F and Series G warrants to purchase shares of common stock were exercised by investors at an exercise price of $0.495 and $0.682 per share, resulting in the issuance of 18,381,177 shares of common stock for proceeds of approximately $9,469,000.
[7]	On February 3, 2021, 17,303 shares of Series B Convertible Preferred Stock were converted into 3,112,923 shares of common stock.

Subsequent Events - Schedule _2

Subsequent Events - Schedule of Outstanding Common Stock (Details) (Parenthetical) - USD ($)		Feb. 03, 2021	Apr. 12, 2019	Apr. 08, 2019	Jan. 31, 2021	Mar. 04, 2021	Dec. 31, 2019	Dec. 31, 2020	Jul. 28, 2020	Jun. 05, 2020	Mar. 27, 2019
Common stock purchase price per share										$ 0.45
Shares issued during the period new issue value							$ 6,335,000
Warrants exercise price								$ 1.82	$ 0.495
Common stock, par value							$ 0.0001	$ 0.0001		0.0001	$ 0.0001
Warrants to purchase								26,705,502	274,029
Maximum [Member]
Warrants exercise price									$ 2.25
Underwritten Public Offering [Member]
Common stock purchase price per share				$ 5
Number of stocks issued				486,957
Over-Allotment Option [Member]
Common stock purchase price per share			$ 5
Number of stocks issued			12,393
Common Stock [Member]
Number of stocks issued							3,039,161
Shares issued during the period new issue value	[1]
Series B Convertible Preferred Stock [Member]
Shares issued during the period new issue value
Series F Warrants [Member]
Common stock purchase price per share										0.45
Warrants exercise price								$ 0.50
Common stock, par value										$ 0.0001
Warrants to purchase								22,688,900		1
Subsequent Event [Member]
Investor agreed to invest		$ 900,000
Common stock purchase price per share		$ 0.6708
Sale of common stock					$ 323,000
Common stock, par value		0.0001
Subsequent Event [Member] | Underwriter [Member] | Maximum [Member]
Warrants exercise price		$ 0.682
Option to purchase up to additional units		4,354,838
Warrants to purchase		1,669,355
Subsequent Event [Member] | Underwritten Public Offering [Member] | Alliance Global Partners [Member]
Common stock purchase price per share		$ 0.62
Number of stocks issued		29,032,258
Warrants exercise price		$ 0.682
Common stock, par value		$ 0.0001
Subsequent Event [Member] | Over-Allotment Option [Member] | Underwriter [Member]
Net proceeds from exercise of warrants		$ 18,900,000
Subsequent Event [Member] | Common Stock [Member]
Number of stocks issued	[2]					33,387,096
Shares issued during the period new issue value	[2]					$ 20,700,000
Subsequent Event [Member] | Common Stock [Member] | Underwriter [Member]
Number of stocks issued		4,354,838
Subsequent Event [Member] | Series B Convertible Preferred Stock [Member]
Shares of common stock issued		17,303
Option to purchase up to additional units		3,112,923
Subsequent Event [Member] | Series F Warrants [Member]
Warrants exercise price		$ 0.495
Subsequent Event [Member] | Series G Warrants [Member]
Warrants exercise price		$ 0.682
Subsequent Event [Member] | Series G Warrants [Member] | Underwriter [Member]
Warrants to purchase		2,177,419
Subsequent Event [Member] | Series F and Series G Warrants [Member]
Net proceeds from exercise of warrants		$ 9,469,000
Subsequent Event [Member] | Series F and Series G Warrants [Member] | Common Stock [Member]
Number of stocks issued		18,381,177
Subsequent Event [Member] | ATM Sales Agreement [Member]
Number of stocks issued		12,277,844
Shares issued during the period new issue value		$ 5,659,000
[1]	Represents an amount less than $1
[2]	On February 3, 2021, the Company entered into an underwriting agreement with A.G.P./Alliance Global Partners, relating to an underwritten public offering (the "Offering") of 29,032,258 units ("Units"), with each Unit being comprised of one share of the Company's common stock, par value $0.0001 per share, and one Series G warrant to purchase one-half of one share of Common Stock. The offering price to the public was $0.62 per Unit. The Series G Warrants are immediately exercisable at a price of $0.682 per share, subject to adjustment in certain circumstances, and expire five years from the date of issuance. The Offering closed on February 8, 2021. The Company granted the Underwriter a 45-day option to purchase up to an additional 4,354,838 Units consisting of 4,354,838 shares of Common Stock and Series G Warrants to purchase 2,177,419 shares of common stock in the Offering, which the Underwriter exercised in full on February 4, 2021. The Company granted the Underwriter a compensation warrant to purchase up to 1,669,355 shares of Common Stock. The Underwriter Warrants have an exercise price of $0.682 per share and are exercisable immediately and for five years from the date of effectiveness of the registration statement in connection with the Offering. The net proceeds to the Company from the Offering, after giving effect to the exercise of the Underwriter's over-allotment option, were approximately $18.9 million, after deducting underwriting discounts and commissions and payment of other estimated expenses associated with the Offering, but excluding the proceeds, if any, from the exercise of Series G Warrants sold in the Offering.